MUK nine b: OPTIMUM. A phase II study evaluating multiple novel agentsoptimised combination of biological therapy in newly diagnosed high risk multiple myeloma and plasma cell leukaemia

Trial Profile

MUK nine b: OPTIMUM. A phase II study evaluating multiple novel agentsoptimised combination of biological therapy in newly diagnosed high risk multiple myeloma and plasma cell leukaemia

Recruiting
Phase of Trial: Phase II

Latest Information Update: 11 Oct 2017

At a glance

  • Drugs Bortezomib (Primary) ; Daratumumab (Primary) ; Dexamethasone (Primary) ; Lenalidomide (Primary) ; Cyclophosphamide; Filgrastim; Melphalan
  • Indications Multiple myeloma; Plasma cell leukaemia
  • Focus Therapeutic Use
  • Acronyms MUKnineb; OPTIMUM
  • Most Recent Events

    • 11 Oct 2017 According to a SkylineDx media release, The Institute of Cancer Research, London (ICR) and University of Leeds will use MMprofiler™ with SKY92, SkylineDx's prognostic tool to risk-stratify patients with multiple myeloma.
    • 10 Oct 2017 According to a media release from The Institute of Cancer Research, Dr Martin Kaiser, Senior Researcher at the ICR is the Chief Investigator of the trial.
    • 10 Oct 2017 Status changed from not yet recruiting to recruiting, according to a media release from The Institute of Cancer Research.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top